aldosterone has been researched along with Inflammation in 143 studies
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To address the cardiovascular mechanisms involved in response to an angiotensin II receptor antagonist, losartan, and continuous positive airway pressure (CPAP) as add-on treatment for hypertension and OSA." | 9.22 | Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial. ( Lindberg, C; Manhem, K; Peker, Y; Rosengren, A; Thunström, E; Yucel-Lindberg, T, 2016) |
| "To evaluate the effects of canrenone compared to placebo on blood pressure control, some non-conventional biomarkers in cardiovascular stratification, and on metalloproteinases in patients affected by metabolic syndrome." | 9.20 | The effects of canrenone on inflammatory markers in patients with metabolic syndrome. ( Bianchi, L; D'Angelo, A; Derosa, G; Maffioli, P; Romano, D, 2015) |
| " Angiotensin II, the principal effector peptide of the RAAS, has far-reaching effects on vascular structure, growth and fibrosis, and is a key regulator of vascular remodeling and inflammation." | 8.83 | Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. ( Duprez, DA, 2006) |
| "Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II." | 7.78 | Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012) |
| "These results suggest that aldosterone may play a critical role in atherogenesis subsequent to oxidative stress in part independent of angiotensin II-mediated signaling, and that eplerenone could prevent atherosclerosis by attenuating oxidative stress and inflammation." | 7.73 | Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. ( Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T, 2006) |
| "The aim of this study was to assess the effects of the Na+-H+ exchange inhibitor cariporide on left ventricular (LV) morphology and function as well as inflammation in rabbits with heart failure." | 7.72 | Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction. ( Busch, AE; Gerl, M; Licher, T; Ruetten, H; Rungwerth, K; Schäfer, S; Schindler, U, 2004) |
| "Sepsis is an extensive life-threatening illness that occurs due to an abnormal host response that extends through the initial storm of inflammation and oxidative stress and terminates at the late stage of immunosuppression." | 5.72 | Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis. ( Ahmed, AF; Al-Kadi, A; El-Daly, M; El-Tahawy, NFG; Khalifa, MMA, 2022) |
| "Hyperaldosteronism is suggested to cause inflammation and metabolic dysregulation, and might contribute to CVD development in obese individuals." | 5.56 | Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity. ( Danser, AHJ; de Graaf, J; Deinum, J; Joosten, LAB; Netea, MG; Riksen, NP; Rutten, J; Schraa, K; Ter Horst, R; van den Munckhof, ICL; van der Heijden, CDCC, 2020) |
| "1:1 matched primary aldosteronism patients demonstrated significantly (p < 0." | 5.46 | Associations of aldosterone and renin concentrations with inflammation-the Study of Health in Pomerania and the German Conn's Registry. ( Adolf, C; Grotevendt, A; Hannemann, A; Hoffmann, W; Nauck, M; Quinkler, M; Reincke, M; Rettig, R; Wallaschofski, H, 2017) |
| " Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients." | 5.46 | Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. ( Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017) |
| "Aldosterone-salt treatment induces not only hypertension but also extensive inflammation that contributes to fibrosis in the rat kidney." | 5.40 | Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in aldosterone-salt-treated rats. ( Doi, S; Doi, T; Kohno, N; Masaki, T; Nakashima, A; Ueno, T; Yokoyama, Y, 2014) |
| "The impact of 4HCH on the hyperaldosteronism, inflammation, and kidney injury provides new insights for future development of therapeutic strategies in resistant hypertension." | 5.40 | 4-Hydroxychalcone attenuates hyperaldosteronism, inflammation, and renal injury in cryptochrome-null mice. ( Dai, B; Li, X; Liu, Y; Qu, Q; Yang, B; Zhang, F, 2014) |
| "Aldosterone promotes atherosclerosis in animal models, but the mechanisms are poorly understood." | 5.39 | Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. ( Armani, A; Bagley, J; Caprio, M; Carmeliet, P; Chen, WS; Galayda, C; Jaffe, IZ; McGraw, AP; Nickerson, H, 2013) |
| "In the course of the development of familial Mediterranean fever in presence of amyloidosis, the inhibition of mineralocorticoid function, and constantly elevated IL-6 levels, which gradually progresses bringing to an exhaustion of that function and to the dissociation of the adaptative-regulatory homeostasis." | 5.38 | [The role of aldosterone and IL-6 in the pathogenesis of inflammation in familial Mediterranean fever]. ( Dzhndoian, ZT; Martirosian, NG, 2012) |
| "Aldosterone is a mineral corticoid hormone that is produced in response to angiotensin-II, and like angiotensin-II, stimulates inflammation, oxidative stress, and fibrosis by activating nuclear factor-kappaB and activating protein-1." | 5.35 | Crosstalk between the heme oxygenase system, aldosterone, and phospholipase C in hypertension. ( Jadhav, A; Lane, N; Ndisang, JF, 2008) |
| "Aldosterone is a mineralocorticoid hormone that regulates blood pressure and salt/water balance." | 5.33 | Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. ( Fasshauer, M; Jäger, J; Klein, J; Kraus, D; Meier, B, 2005) |
| "To address the cardiovascular mechanisms involved in response to an angiotensin II receptor antagonist, losartan, and continuous positive airway pressure (CPAP) as add-on treatment for hypertension and OSA." | 5.22 | Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial. ( Lindberg, C; Manhem, K; Peker, Y; Rosengren, A; Thunström, E; Yucel-Lindberg, T, 2016) |
| "To evaluate the effects of canrenone compared to placebo on blood pressure control, some non-conventional biomarkers in cardiovascular stratification, and on metalloproteinases in patients affected by metabolic syndrome." | 5.20 | The effects of canrenone on inflammatory markers in patients with metabolic syndrome. ( Bianchi, L; D'Angelo, A; Derosa, G; Maffioli, P; Romano, D, 2015) |
| "In RALES, low doses of the mineralocorticoid receptor (MR) antagonist spironolactone, added to standard of care for severe heart failure, improved survival by 30% and lowered hospitalization by 35%." | 5.11 | RALES, EPHESUS and redox. ( Funder, JW, 2005) |
| " Angiotensin II, the principal effector peptide of the RAAS, has far-reaching effects on vascular structure, growth and fibrosis, and is a key regulator of vascular remodeling and inflammation." | 4.83 | Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. ( Duprez, DA, 2006) |
| "Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II." | 3.78 | Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012) |
| "Hyperhomocysteinemia, neurohormonal activation, inflammation and altered fibrinolysis have been linked to atherothrombosis as well as to myocardial fibrosis and heart failure." | 3.75 | Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. ( Benjamin, EJ; D'Agostino, RB; Hayes, L; Jacques, P; Joseph, J; Levy, D; Pencina, MJ; Selhub, J; Tofler, GH; Vasan, RS; Wang, TJ, 2009) |
| "We evaluated 2119 Framingham Offspring Study participants (mean age, 57 years; 57% women) who underwent measurements of biomarkers of inflammation (C-reactive protein), hemostasis (fibrinogen and plasminogen activator inhibitor-1), neurohormonal activation (B-type natriuretic peptide), and renin-angiotensin-aldosterone system (aldosterone and renin modeled as a ratio [ARR]) and echocardiography at a routine examination." | 3.74 | Relations of biomarkers representing distinct biological pathways to left ventricular geometry. ( Aragam, J; Benjamin, EJ; Gona, P; Larson, MG; Levy, D; Lieb, W; Tofler, GH; Vasan, RS; Velagaleti, RS; Wang, TJ, 2008) |
| "These results suggest that aldosterone may play a critical role in atherogenesis subsequent to oxidative stress in part independent of angiotensin II-mediated signaling, and that eplerenone could prevent atherosclerosis by attenuating oxidative stress and inflammation." | 3.73 | Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. ( Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T, 2006) |
| "The aim of this study was to assess the effects of the Na+-H+ exchange inhibitor cariporide on left ventricular (LV) morphology and function as well as inflammation in rabbits with heart failure." | 3.72 | Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction. ( Busch, AE; Gerl, M; Licher, T; Ruetten, H; Rungwerth, K; Schäfer, S; Schindler, U, 2004) |
| "Primary aldosteronism (PA) and diabetes mellitus (DM) are clinical conditions that increase cardiovascular risk." | 3.01 | Secondary diabetes mellitus due to primary aldosteronism. ( Moustaki, M; Paschou, SA; Vakali, EC; Vryonidou, A, 2023) |
| "Salt and inflammation are placed in the middle of the mosaic because both factors influence each of the remaining pieces." | 2.82 | Mosaic theory revised: inflammation and salt play central roles in arterial hypertension. ( Benitah, JP; Hengel, FE; Wenzel, UO, 2022) |
| "Inflammation is considered as a major effector of arterial damage brought about by salt excess in animal models." | 2.78 | Procalcitonin and the inflammatory response to salt in essential hypertension: a randomized cross-over clinical trial. ( Cutrupi, S; Leonardis, D; Mallamaci, F; Pizzini, P; Tripepi, G; Zoccali, C, 2013) |
| "Hypertension is characteristically associated with vascular dysfunction, cardiovascular remodelling, renal dysfunction, and stimulation of the sympathetic nervous system." | 2.66 | Oxidative Stress: A Unifying Paradigm in Hypertension. ( Alves-Lopes, R; Camargo, LL; Montezano, AC; Neves, KB; Rios, FJ; Touyz, RM, 2020) |
| "Heart failure is a complex syndrome that affects almost all organs and systems of the body." | 2.50 | [Organ damage and cardiorenal syndrome in acute heart failure]. ( Casado Cerrada, J; Pérez Calvo, JI, 2014) |
| "Aldosterone antagonists have been highly successful in treating congestive heart failure and resistant hypertension." | 2.47 | Mineralocorticoid receptor blockade in chronic kidney disease. ( Bomback, AS; Klemmer, PJ; Volk, MJ, 2011) |
| "Systolic heart failure is a feed-forward phenomenon with devastating consequences." | 2.45 | Pharmacological treatment for heart failure: a view from the brain. ( Felder, RB; Wei, SG; Yu, Y; Zhang, ZH, 2009) |
| "Atherosclerosis is characterized by the thickening of the arterial wall and is the primary cause of coronary artery disease and cerebrovascular disease, two of the most common causes of illness and death worldwide." | 2.44 | Translating molecular discoveries into new therapies for atherosclerosis. ( Daugherty, A; Rader, DJ, 2008) |
| "Aldosterone is a pro-inflammatory factor that can participate in the vascular inflammatory process associated with different pathologies including hypertension through activation of the NFkappaB system, which mediates the vascular production of different cytokines." | 2.44 | Aldosterone and the vascular system. ( Ballesteros, S; Cachofeiro, V; de Las Heras, N; Fernández-Tresguerres, J; Lahera, V; Martín-Fernández, B; Miana, M, 2008) |
| "Inflammation is associated with fibrosis." | 2.43 | [PPARs and fibrosis]. ( Kurabayashi, M, 2005) |
| "Heart failure is a major health problem of epidemic proportions." | 2.42 | Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. ( Ahokas, RA; Gerling, IC; Guntaka, RV; Kiani, MF; Postlethwaite, AE; Sun, Y; Warrington, KJ; Weber, KT, 2003) |
| "Obesity is a common problem in much of the western world today in that is linked directly with several disease processes, notably, hypertension." | 2.42 | Hypertension and obesity. ( Aneja, A; El-Atat, F; McFarlane, SI; Sowers, JR, 2004) |
| "Aldosterone was significantly associated with all-cause mortality (hazard ratio per standard deviation increase: 1." | 1.91 | Association of Aldosterone with Mortality in the General Population. ( Bidlingmaier, M; Heier, M; Herder, C; Koenig, W; Meisinger, C; Peters, A; Rathmann, W; Reincke, M; Roden, M; Seissler, J; Sujana, C; Then, C; Thorand, B, 2023) |
| "Renal fibrosis is an inevitable process in the progression of chronic kidney disease (CKD)." | 1.91 | Esaxerenone Inhibits Renal Angiogenesis and Endothelial-Mesenchymal Transition via the VEGFA and TGF-β1 Pathways in Aldosterone-Infused Mice. ( Chang, J; Chang, Y; Fan, L; Gao, X; Liu, Z; Shimosawa, T; Xu, Q; Yang, F; Zhang, C, 2023) |
| "Sepsis is an extensive life-threatening illness that occurs due to an abnormal host response that extends through the initial storm of inflammation and oxidative stress and terminates at the late stage of immunosuppression." | 1.72 | Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis. ( Ahmed, AF; Al-Kadi, A; El-Daly, M; El-Tahawy, NFG; Khalifa, MMA, 2022) |
| "Stroke is a severe and frequent complication of Fabry disease (FD), affecting both males and females." | 1.56 | Fabry disease patients have an increased risk of stroke in the COVID-19 ERA. A hypothesis. ( Bonardo, P; Reisin, RC; Rozenfeld, P, 2020) |
| "Hyperaldosteronism is suggested to cause inflammation and metabolic dysregulation, and might contribute to CVD development in obese individuals." | 1.56 | Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity. ( Danser, AHJ; de Graaf, J; Deinum, J; Joosten, LAB; Netea, MG; Riksen, NP; Rutten, J; Schraa, K; Ter Horst, R; van den Munckhof, ICL; van der Heijden, CDCC, 2020) |
| "Aldosterone has been proved a risk factor of fibrosis and inflammation." | 1.51 | Aldosterone induced up-expression of ICAM-1 and ET-1 in pancreatic islet endothelium may associate with progression of T2D. ( Chen, L; Cui, C; Guo, X; He, Q; Hou, X; Hu, H; Liu, F; Qin, J; Song, J; Wang, J; Yan, F, 2019) |
| "Primary aldosteronism (PA) is a disease characterized by high aldosterone levels caused by benign adrenal tumors being the most frequent cause of secondary hypertension." | 1.46 | Primary aldosteronism patients show skin alterations and abnormal activation of glucocorticoid receptor in keratinocytes. ( Bigas, J; Boix, J; Caroccia, B; Citton, M; Iacobone, M; Pérez, P; Rossi, GP; Sevilla, LM; Torresan, F, 2017) |
| " Longer duration or higher dosage of spironolactone seems to be more effective in improving cardiovascular system status in PD patients." | 1.46 | Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients. ( Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B, 2017) |
| "1:1 matched primary aldosteronism patients demonstrated significantly (p < 0." | 1.46 | Associations of aldosterone and renin concentrations with inflammation-the Study of Health in Pomerania and the German Conn's Registry. ( Adolf, C; Grotevendt, A; Hannemann, A; Hoffmann, W; Nauck, M; Quinkler, M; Reincke, M; Rettig, R; Wallaschofski, H, 2017) |
| "Treatment with rotenone, an inhibitor of mitochondrial complex I, significantly attenuated oxidative stress, mitochondrial dysfunction, and inflammasome response in aldosterone-infused rats." | 1.42 | Rotenone Attenuates Renal Injury in Aldosterone-Infused Rats by Inhibiting Oxidative Stress, Mitochondrial Dysfunction, and Inflammasome Activation. ( Ding, W; Wang, B; Xu, C; Zhang, M, 2015) |
| "The impact of 4HCH on the hyperaldosteronism, inflammation, and kidney injury provides new insights for future development of therapeutic strategies in resistant hypertension." | 1.40 | 4-Hydroxychalcone attenuates hyperaldosteronism, inflammation, and renal injury in cryptochrome-null mice. ( Dai, B; Li, X; Liu, Y; Qu, Q; Yang, B; Zhang, F, 2014) |
| "Aldosterone-salt treatment induces not only hypertension but also extensive inflammation that contributes to fibrosis in the rat kidney." | 1.40 | Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in aldosterone-salt-treated rats. ( Doi, S; Doi, T; Kohno, N; Masaki, T; Nakashima, A; Ueno, T; Yokoyama, Y, 2014) |
| "Canrenone is a derivative of spironolactone with lower antiandrogen activity." | 1.40 | Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs. ( Armanini, D; Bordin, L; Clari, G; Donà, G; Sabbadin, C, 2014) |
| "Aldosterone plays a crucial role in cardiovascular disease." | 1.39 | Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. ( Berger, S; Lohmann, C; Lüscher, TF; Matter, CM; Miranda, MX; Nussberger, J; Ruschitzka, F; Schäfer, N; van Tits, LJ; Vergopoulos, A; Verrey, F; Winnik, S, 2013) |
| "Aldosterone promotes atherosclerosis in animal models, but the mechanisms are poorly understood." | 1.39 | Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. ( Armani, A; Bagley, J; Caprio, M; Carmeliet, P; Chen, WS; Galayda, C; Jaffe, IZ; McGraw, AP; Nickerson, H, 2013) |
| "In the course of the development of familial Mediterranean fever in presence of amyloidosis, the inhibition of mineralocorticoid function, and constantly elevated IL-6 levels, which gradually progresses bringing to an exhaustion of that function and to the dissociation of the adaptative-regulatory homeostasis." | 1.38 | [The role of aldosterone and IL-6 in the pathogenesis of inflammation in familial Mediterranean fever]. ( Dzhndoian, ZT; Martirosian, NG, 2012) |
| "Aldosterone induced an increase in adhesion molecule protein content and promoted monocyte adhesion to VSMCs, responses that were inhibited an by cholesterol depletion, caveolin-1 deficiency, AG1296 and PP2, a c-Src inhibitor." | 1.37 | Vascular proinflammatory responses by aldosterone are mediated via c-Src trafficking to cholesterol-rich microdomains: role of PDGFR. ( Briones, AM; Callera, GE; He, Y; Montezano, AC; Schiffrin, EL; Tostes, RC; Touyz, RM; Yogi, A, 2011) |
| "Spironolactone treatment reversed all the above effects." | 1.37 | A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. ( Cachofeiro, V; Díez, J; Fortuno, MA; Lahera, V; López-Andrés, N; Martin-Fernandez, B; Rossignol, P; Zannad, F, 2011) |
| "In patients with dilated cardiomyopathy (DCM) abnormal myocardial blood flow (MBF) has been associated with coronary microvascular dysfunction." | 1.36 | Increased plasma levels of osteopontin are associated with activation of the renin-aldosterone system and with myocardial and coronary microvascular damage in dilated cardiomyopathy. ( Cabiati, M; Caselli, C; Del Ry, S; Giannessi, D; Iervasi, A; Maltinti, M; Mazzone, AM; Neglia, D; Prontera, C, 2010) |
| "Aldosterone has been correlated with increased oxidative stress, endothelial inflammation, and fibrosis, particularly in patients with heart disease." | 1.36 | Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. ( Becerra, E; Carvajal, CA; Fardella, CE; García, L; Jalil, J; Lavandero, S; Mellado, R; Mosso, L; Ocaranza, MP; Solis, M; Stehr, CB, 2010) |
| "Aldosterone is a mineral corticoid hormone that is produced in response to angiotensin-II, and like angiotensin-II, stimulates inflammation, oxidative stress, and fibrosis by activating nuclear factor-kappaB and activating protein-1." | 1.35 | Crosstalk between the heme oxygenase system, aldosterone, and phospholipase C in hypertension. ( Jadhav, A; Lane, N; Ndisang, JF, 2008) |
| "Aldosterone plays a key role in the pathogenesis of Ang II-induced organ damage." | 1.33 | Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. ( Al-Saadi, N; Dechend, R; Fiebeler, A; Hilfenhaus, G; Jeng, AY; Luft, FC; Maser-Gluth, C; Meiners, S; Muller, DN; Nussberger, J; Rong, S; Shagdarsuren, E; Webb, RL; Wellner, M, 2005) |
| "Aldosterone is a mineralocorticoid hormone that regulates blood pressure and salt/water balance." | 1.33 | Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. ( Fasshauer, M; Jäger, J; Klein, J; Kraus, D; Meier, B, 2005) |
| "We examined the relationship between chronic fatigue syndrome (CFS) and allostatic load in a population-based, case-control study of 43 CFS patients and 60 nonfatigued, healthy controls from Wichita, KS, USA." | 1.33 | Chronic fatigue syndrome and high allostatic load. ( de Souza Coelho, L; Goertzel, BN; Gurbaxani, BM; Jones, JF; Maloney, EM; Pennachin, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (5.59) | 18.7374 |
| 1990's | 1 (0.70) | 18.2507 |
| 2000's | 40 (27.97) | 29.6817 |
| 2010's | 71 (49.65) | 24.3611 |
| 2020's | 23 (16.08) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Faour, WH | 1 |
| Choaib, A | 1 |
| Issa, E | 1 |
| Choueiry, FE | 1 |
| Shbaklo, K | 1 |
| Alhajj, M | 1 |
| Sawaya, RT | 1 |
| Harhous, Z | 1 |
| Alefishat, E | 1 |
| Nader, M | 1 |
| Stanley, JC | 1 |
| Hengel, FE | 1 |
| Benitah, JP | 1 |
| Wenzel, UO | 1 |
| Moustaki, M | 1 |
| Paschou, SA | 1 |
| Vakali, EC | 1 |
| Vryonidou, A | 1 |
| Epstein, M | 1 |
| Kovesdy, CP | 1 |
| Clase, CM | 1 |
| Sood, MM | 1 |
| Pecoits-Filho, R | 1 |
| Piazza, M | 3 |
| Hanssen, NMJ | 3 |
| Scheijen, JLJM | 3 |
| Vd Waarenburg, M | 3 |
| Caroccia, B | 4 |
| Seccia, TM | 3 |
| Stehouwer, CDA | 3 |
| Rossi, GP | 4 |
| Schalkwijk, CG | 3 |
| Then, C | 1 |
| Herder, C | 1 |
| Heier, M | 1 |
| Meisinger, C | 1 |
| Koenig, W | 1 |
| Rathmann, W | 1 |
| Sujana, C | 1 |
| Roden, M | 1 |
| Bidlingmaier, M | 1 |
| Seissler, J | 1 |
| Thorand, B | 1 |
| Peters, A | 1 |
| Reincke, M | 2 |
| Launonen, H | 1 |
| Luiskari, L | 1 |
| Linden, J | 1 |
| Siltari, A | 1 |
| Salmenkari, H | 1 |
| Korpela, R | 1 |
| Vapaatalo, H | 1 |
| Rivera, A | 1 |
| Vega, C | 1 |
| Ramos-Rivera, A | 1 |
| Maldonado, ER | 1 |
| Prado, GN | 1 |
| Karnes, HE | 1 |
| Fesko, YA | 1 |
| Snyder, LM | 1 |
| Alper, SL | 1 |
| Romero, JR | 2 |
| Gao, X | 1 |
| Chang, J | 1 |
| Chang, Y | 1 |
| Fan, L | 1 |
| Liu, Z | 1 |
| Zhang, C | 1 |
| Shimosawa, T | 1 |
| Yang, F | 1 |
| Xu, Q | 1 |
| Barrera-Chimal, J | 1 |
| Jaisser, F | 7 |
| Mohamed, DM | 2 |
| Shaqura, M | 2 |
| Li, X | 3 |
| Shakibaei, M | 2 |
| Beyer, A | 2 |
| Treskatsch, S | 2 |
| Schäfer, M | 2 |
| Mousa, SA | 2 |
| Bornstein, SR | 1 |
| Dalan, R | 1 |
| Hopkins, D | 1 |
| Mingrone, G | 1 |
| Boehm, BO | 1 |
| Unkart, JT | 1 |
| Allison, MA | 1 |
| Abdelmalek, JA | 1 |
| Jenny, NS | 1 |
| McClelland, RL | 1 |
| Budoff, M | 1 |
| Ix, JH | 1 |
| Rifkin, DE | 1 |
| Henry, BM | 1 |
| Vikse, J | 1 |
| Benoit, S | 1 |
| Favaloro, EJ | 1 |
| Lippi, G | 1 |
| Touyz, RM | 3 |
| Rios, FJ | 1 |
| Alves-Lopes, R | 1 |
| Neves, KB | 1 |
| Camargo, LL | 1 |
| Montezano, AC | 2 |
| van der Heijden, CDCC | 1 |
| Ter Horst, R | 1 |
| van den Munckhof, ICL | 1 |
| Schraa, K | 1 |
| de Graaf, J | 1 |
| Joosten, LAB | 1 |
| Danser, AHJ | 1 |
| Netea, MG | 1 |
| Deinum, J | 1 |
| Rutten, J | 1 |
| Riksen, NP | 1 |
| Li, L | 1 |
| Buhrmann, C | 1 |
| Li, S | 2 |
| Cao, W | 1 |
| Wang, B | 2 |
| Zhan, E | 1 |
| Xu, J | 1 |
| Ostermann, M | 1 |
| Lumlertgul, N | 1 |
| Forni, LG | 1 |
| Hoste, E | 1 |
| Reisin, RC | 1 |
| Rozenfeld, P | 1 |
| Bonardo, P | 1 |
| Harrison, DG | 1 |
| Coffman, TM | 1 |
| Wilcox, CS | 1 |
| Al-Kadi, A | 1 |
| El-Daly, M | 1 |
| El-Tahawy, NFG | 1 |
| Khalifa, MMA | 1 |
| Ahmed, AF | 1 |
| Grotevendt, A | 1 |
| Wallaschofski, H | 1 |
| Adolf, C | 1 |
| Quinkler, M | 1 |
| Nauck, M | 1 |
| Hoffmann, W | 1 |
| Rettig, R | 1 |
| Hannemann, A | 1 |
| Donderski, R | 1 |
| Stróżecki, P | 1 |
| Sulikowska, B | 1 |
| Grajewska, M | 1 |
| Miśkowiec, I | 1 |
| Stefańska, A | 1 |
| Siódmiak, J | 1 |
| Odrowąż-Sypniewska, G | 1 |
| Manitius, J | 1 |
| Boix, J | 1 |
| Bigas, J | 1 |
| Sevilla, LM | 1 |
| Iacobone, M | 1 |
| Citton, M | 1 |
| Torresan, F | 1 |
| Pérez, P | 1 |
| Buonafine, M | 1 |
| Martínez-Martínez, E | 3 |
| Amador, C | 1 |
| Gravez, B | 1 |
| Ibarrola, J | 1 |
| Fernández-Celis, A | 2 |
| El Moghrabi, S | 1 |
| Rossignol, P | 4 |
| López-Andrés, N | 4 |
| Armanini, D | 5 |
| Sabbadin, C | 4 |
| Donà, G | 3 |
| Bordin, L | 3 |
| Marin, L | 1 |
| Andrisani, A | 2 |
| Ambrosini, G | 2 |
| Zhang, YD | 1 |
| Ding, XJ | 1 |
| Dai, HY | 1 |
| Peng, WS | 1 |
| Guo, NF | 1 |
| Zhang, Y | 2 |
| Zhou, QL | 1 |
| Chen, XL | 1 |
| Pezzani, R | 1 |
| Marzolla, V | 1 |
| Armani, A | 2 |
| Mammi, C | 1 |
| Feraco, A | 1 |
| Caprio, M | 2 |
| Wang, J | 1 |
| Hu, H | 1 |
| Song, J | 1 |
| Yan, F | 1 |
| Qin, J | 1 |
| Guo, X | 1 |
| Cui, C | 1 |
| He, Q | 1 |
| Hou, X | 1 |
| Liu, F | 1 |
| Chen, L | 1 |
| Araos, P | 1 |
| Prado, C | 1 |
| Lozano, M | 1 |
| Figueroa, S | 1 |
| Espinoza, A | 1 |
| Berger, T | 1 |
| Mak, TW | 1 |
| Pacheco, R | 1 |
| Michea, L | 1 |
| Amador, CA | 1 |
| Tzamou, V | 1 |
| Vyssoulis, G | 1 |
| Karpanou, E | 1 |
| Kyvelou, SM | 1 |
| Gialernios, T | 1 |
| Stefanadis, C | 2 |
| McGraw, AP | 1 |
| Bagley, J | 1 |
| Chen, WS | 1 |
| Galayda, C | 1 |
| Nickerson, H | 1 |
| Carmeliet, P | 1 |
| Jaffe, IZ | 1 |
| Schäfer, N | 1 |
| Lohmann, C | 1 |
| Winnik, S | 1 |
| van Tits, LJ | 1 |
| Miranda, MX | 1 |
| Vergopoulos, A | 1 |
| Ruschitzka, F | 1 |
| Nussberger, J | 2 |
| Berger, S | 1 |
| Lüscher, TF | 1 |
| Verrey, F | 1 |
| Matter, CM | 1 |
| Lambers Heerspink, HJ | 1 |
| Wang, X | 1 |
| Zhao, Q | 1 |
| Huang, H | 1 |
| Tang, Y | 1 |
| Xiao, J | 1 |
| Dai, Z | 1 |
| Yu, S | 1 |
| Huang, C | 1 |
| Mallamaci, F | 1 |
| Leonardis, D | 1 |
| Pizzini, P | 1 |
| Cutrupi, S | 1 |
| Tripepi, G | 1 |
| Zoccali, C | 1 |
| Brown, NJ | 4 |
| Zhou, R | 1 |
| Lin, ZH | 1 |
| Jiang, CS | 1 |
| Gong, JX | 1 |
| Chen, LL | 1 |
| Guo, YW | 1 |
| Shen, X | 1 |
| Hao, J | 1 |
| Ren, L | 1 |
| Zhang, L | 1 |
| Kong, D | 1 |
| Hao, L | 1 |
| Clari, G | 1 |
| Doi, T | 1 |
| Doi, S | 1 |
| Nakashima, A | 1 |
| Ueno, T | 1 |
| Yokoyama, Y | 1 |
| Kohno, N | 1 |
| Masaki, T | 1 |
| Ikeda, K | 1 |
| Casado Cerrada, J | 1 |
| Pérez Calvo, JI | 1 |
| Qu, Q | 1 |
| Dai, B | 1 |
| Yang, B | 1 |
| Liu, Y | 1 |
| Zhang, F | 1 |
| Derosa, G | 1 |
| Romano, D | 1 |
| Bianchi, L | 1 |
| D'Angelo, A | 1 |
| Maffioli, P | 1 |
| Bauersachs, J | 1 |
| Toto, R | 1 |
| Martín-Fernández, B | 5 |
| Valero Muñoz, M | 1 |
| de las Heras, N | 4 |
| Ballesteros, S | 4 |
| Lahera, V | 5 |
| Schwenk, MH | 1 |
| Hirsch, JS | 1 |
| Bomback, AS | 3 |
| Cachofeiro, V | 5 |
| Rousseau, E | 1 |
| Álvarez, V | 1 |
| Calvier, L | 2 |
| Leroy, C | 1 |
| Miana, M | 4 |
| Jurado-López, R | 1 |
| Briones, AM | 2 |
| Zannad, F | 3 |
| Morgado-Pascual, JL | 1 |
| Rayego-Mateos, S | 1 |
| Valdivielso, JM | 1 |
| Ortiz, A | 1 |
| Egido, J | 2 |
| Ruiz-Ortega, M | 1 |
| Srinivasa, S | 1 |
| Fitch, KV | 1 |
| Wong, K | 1 |
| Torriani, M | 1 |
| Mayhew, C | 1 |
| Stanley, T | 1 |
| Lo, J | 1 |
| Adler, GK | 4 |
| Grinspoon, SK | 1 |
| Muñoz-Durango, N | 1 |
| Vecchiola, A | 1 |
| Gonzalez-Gomez, LM | 1 |
| Simon, F | 1 |
| Riedel, CA | 1 |
| Fardella, CE | 2 |
| Kalergis, AM | 1 |
| Ding, W | 1 |
| Xu, C | 1 |
| Zhang, M | 1 |
| Peng, W | 1 |
| Ao, X | 1 |
| Dai, H | 1 |
| Yuan, L | 1 |
| Huang, X | 1 |
| Zhou, Q | 1 |
| Farman, N | 1 |
| Rubio-Navarro, A | 1 |
| Cortegano, I | 1 |
| Alía, M | 1 |
| Cannata-Ortiz, P | 1 |
| Olivares-Álvaro, E | 1 |
| de Andrés, B | 1 |
| Gaspar, ML | 1 |
| Moreno, JA | 1 |
| So, KM | 1 |
| Lee, Y | 1 |
| Bok, JD | 1 |
| Kim, EB | 1 |
| Chung, MI | 1 |
| Calò, LA | 3 |
| Dinh, QN | 1 |
| Young, MJ | 1 |
| Evans, MA | 1 |
| Drummond, GR | 1 |
| Sobey, CG | 1 |
| Chrissobolis, S | 1 |
| Thunström, E | 1 |
| Manhem, K | 1 |
| Yucel-Lindberg, T | 1 |
| Rosengren, A | 1 |
| Lindberg, C | 1 |
| Peker, Y | 1 |
| Sanchez-Lemus, E | 1 |
| Murakami, Y | 1 |
| Larrayoz-Roldan, IM | 1 |
| Moughamian, AJ | 1 |
| Pavel, J | 1 |
| Nishioku, T | 1 |
| Saavedra, JM | 1 |
| Velagaleti, RS | 1 |
| Gona, P | 1 |
| Levy, D | 2 |
| Aragam, J | 1 |
| Larson, MG | 1 |
| Tofler, GH | 2 |
| Lieb, W | 1 |
| Wang, TJ | 2 |
| Benjamin, EJ | 2 |
| Vasan, RS | 2 |
| Gekle, M | 1 |
| Grossmann, C | 1 |
| Klemmer, PJ | 2 |
| Klinge, U | 1 |
| Theuer, S | 1 |
| Krott, E | 1 |
| Fiebeler, A | 3 |
| Joseph, J | 1 |
| Pencina, MJ | 1 |
| Hayes, L | 1 |
| Jacques, P | 1 |
| Selhub, J | 1 |
| D'Agostino, RB | 1 |
| Felder, RB | 1 |
| Yu, Y | 1 |
| Zhang, ZH | 1 |
| Wei, SG | 1 |
| Nakamura, T | 1 |
| Kataoka, K | 1 |
| Fukuda, M | 1 |
| Nako, H | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Ichijo, H | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Gomez Sanchez, EP | 1 |
| Hilgers, KF | 1 |
| Hoppmann, J | 1 |
| Perwitz, N | 1 |
| Meier, B | 2 |
| Fasshauer, M | 2 |
| Hadaschik, D | 1 |
| Lehnert, H | 1 |
| Klein, J | 2 |
| Del Ry, S | 1 |
| Giannessi, D | 1 |
| Maltinti, M | 1 |
| Cabiati, M | 1 |
| Prontera, C | 1 |
| Iervasi, A | 1 |
| Caselli, C | 1 |
| Mazzone, AM | 1 |
| Neglia, D | 1 |
| Briet, M | 2 |
| Schiffrin, EL | 5 |
| Gilbert, KC | 1 |
| Kadomatsu, K | 1 |
| Matsui, T | 1 |
| Takeuchi, M | 1 |
| Yamagishi, S | 1 |
| Tirosh, A | 1 |
| Garg, R | 1 |
| Mohammed, SF | 1 |
| Ohtani, T | 1 |
| Korinek, J | 1 |
| Lam, CS | 1 |
| Larsen, K | 1 |
| Simari, RD | 1 |
| Valencik, ML | 1 |
| Burnett, JC | 1 |
| Redfield, MM | 1 |
| Stehr, CB | 1 |
| Mellado, R | 1 |
| Ocaranza, MP | 1 |
| Carvajal, CA | 1 |
| Mosso, L | 1 |
| Becerra, E | 1 |
| Solis, M | 1 |
| García, L | 1 |
| Lavandero, S | 1 |
| Jalil, J | 1 |
| Gamliel-Lazarovich, A | 2 |
| Gantman, A | 2 |
| Coleman, R | 2 |
| Jeng, AY | 2 |
| Kaplan, M | 1 |
| Keidar, S | 2 |
| Fusaro, M | 1 |
| Davis, PA | 1 |
| Withers, SB | 1 |
| Agabiti-Rosei, C | 1 |
| Livingstone, DM | 1 |
| Little, MC | 1 |
| Aslam, R | 1 |
| Malik, RA | 1 |
| Heagerty, AM | 1 |
| Gomez-Sanchez, EP | 1 |
| Volk, MJ | 1 |
| Kurdi, M | 1 |
| Booz, GW | 1 |
| Callera, GE | 1 |
| Yogi, A | 1 |
| He, Y | 1 |
| Tostes, RC | 1 |
| Irita, J | 1 |
| Okura, T | 1 |
| Jotoku, M | 1 |
| Nagao, T | 1 |
| Enomoto, D | 1 |
| Kurata, M | 1 |
| Desilva, VR | 1 |
| Miyoshi, K | 1 |
| Matsui, Y | 1 |
| Uede, T | 1 |
| Denhardt, DT | 1 |
| Rittiling, SR | 1 |
| Higaki, J | 2 |
| Fortuno, MA | 1 |
| Díez, J | 1 |
| Cooper, JN | 1 |
| Tepper, P | 1 |
| Barinas-Mitchell, E | 1 |
| Woodard, GA | 1 |
| Sutton-Tyrrell, K | 1 |
| Ronconi, V | 1 |
| Turchi, F | 1 |
| Appolloni, G | 1 |
| di Tizio, V | 1 |
| Boscaro, M | 1 |
| Giacchetti, G | 1 |
| Androulakis, E | 1 |
| Tousoulis, D | 1 |
| Papageorgiou, N | 1 |
| Latsios, G | 1 |
| Siasos, G | 1 |
| Tsioufis, C | 1 |
| Giolis, A | 1 |
| Nguyen Dinh Cat, A | 1 |
| Valero-Muñoz, M | 1 |
| Vassallo, D | 1 |
| Davel, AP | 1 |
| Rossoni, LV | 1 |
| Luther, JM | 1 |
| Luo, P | 1 |
| Wang, Z | 1 |
| Cohen, SE | 1 |
| Kim, HS | 1 |
| Fogo, AB | 1 |
| Dzhndoian, ZT | 1 |
| Martirosian, NG | 1 |
| Bay-Richter, C | 1 |
| Hallberg, L | 1 |
| Ventorp, F | 1 |
| Janelidze, S | 1 |
| Brundin, L | 1 |
| Reboul, P | 1 |
| de Boer, RA | 1 |
| Poirier, F | 1 |
| Lacolley, P | 1 |
| Raz-Pasteur, A | 1 |
| Sun, Y | 3 |
| Zhang, J | 1 |
| Lu, L | 1 |
| Chen, SS | 1 |
| Quinn, MT | 1 |
| Weber, KT | 5 |
| Diep, QN | 2 |
| Amiri, F | 2 |
| Cohn, JS | 2 |
| Endemann, D | 2 |
| Neves, MF | 2 |
| Funder, JW | 2 |
| Gerling, IC | 2 |
| Kiani, MF | 1 |
| Guntaka, RV | 1 |
| Ahokas, RA | 2 |
| Postlethwaite, AE | 1 |
| Warrington, KJ | 1 |
| SELYE, H | 1 |
| BAJUSZ, E | 1 |
| JASMIN, G | 1 |
| HIEMEYER, V | 1 |
| KAEHLER, HJ | 1 |
| HUGHES, ER | 1 |
| FRANCHIMONT, P | 1 |
| VANCAUWENBERGE, H | 1 |
| El-Atat, F | 2 |
| Aneja, A | 2 |
| Mcfarlane, S | 1 |
| Sowers, J | 1 |
| McFarlane, SI | 1 |
| Sowers, JR | 1 |
| Hansen, PR | 1 |
| Rieneck, K | 1 |
| Bendtzen, K | 1 |
| Rungwerth, K | 1 |
| Schindler, U | 1 |
| Gerl, M | 1 |
| Schäfer, S | 1 |
| Licher, T | 1 |
| Busch, AE | 1 |
| Ruetten, H | 1 |
| Chhokar, VS | 1 |
| Bhattacharya, SK | 1 |
| Myers, LK | 1 |
| Xing, Z | 1 |
| Smith, RA | 1 |
| Kurabayashi, M | 1 |
| Shagdarsuren, E | 2 |
| Rong, S | 1 |
| Hilfenhaus, G | 1 |
| Al-Saadi, N | 1 |
| Dechend, R | 1 |
| Wellner, M | 1 |
| Meiners, S | 1 |
| Maser-Gluth, C | 1 |
| Webb, RL | 1 |
| Luft, FC | 2 |
| Muller, DN | 2 |
| Venco, A | 1 |
| Grandi, AM | 1 |
| Joffe, HV | 1 |
| Lombardi, F | 1 |
| Terranova, P | 1 |
| Kraus, D | 1 |
| Jäger, J | 1 |
| Suzuki, J | 1 |
| Iwai, M | 1 |
| Mogi, M | 1 |
| Oshita, A | 1 |
| Yoshii, T | 1 |
| Horiuchi, M | 1 |
| Maloney, EM | 1 |
| Gurbaxani, BM | 1 |
| Jones, JF | 1 |
| de Souza Coelho, L | 1 |
| Pennachin, C | 1 |
| Goertzel, BN | 1 |
| Duprez, DA | 1 |
| Bens, M | 1 |
| Chassin, C | 1 |
| Vandewalle, A | 1 |
| Rader, DJ | 1 |
| Daugherty, A | 1 |
| Siragy, HM | 1 |
| Xue, C | 1 |
| Fernández-Tresguerres, J | 1 |
| Guo, C | 1 |
| Ricchiuti, V | 1 |
| Lian, BQ | 1 |
| Yao, TM | 1 |
| Coutinho, P | 1 |
| Li, J | 1 |
| Williams, GH | 1 |
| Ndisang, JF | 1 |
| Lane, N | 1 |
| Jadhav, A | 1 |
| El Mabrouk, M | 1 |
| Virdis, A | 1 |
| Lin, YC | 1 |
| Talley, DJ | 1 |
| Villee, CA | 1 |
| Harris, PE | 1 |
| Kendall-Taylor, P | 1 |
| Okamoto, H | 1 |
| Hatta, A | 1 |
| Itoh, N | 1 |
| Ohashi, Y | 1 |
| Arakawa, K | 1 |
| Nakanishi, S | 1 |
| Singer, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Study of a 10-days Fenofibrate Treatment, or Until Discharge From Hospital, Among COVID-19 Infected Patients Requiring Hospitalization[NCT04661930] | Phase 3 | 55 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Time of Recovery and Prognostic Factors of COVID-19 Pneumonia[NCT04324684] | 198 participants (Actual) | Observational | 2020-03-31 | Completed | |||
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Counter-Regulatory Hormonal and Stress Systems in Patients With COVID-19[NCT05736900] | 200 participants (Actual) | Interventional | 2020-09-10 | Completed | |||
| Laparoscopic Bariatric Surgery During Phase 2-3 Covid-19 Pandemic in Italy: a Multicenter, Prospective, Observational Study.[NCT04480034] | 1,600 participants (Anticipated) | Observational | 2020-07-15 | Recruiting | |||
| Acute Kidney Injury in COVID-19 Patients Admitted to the ICU: a Multicenter Cohort Analysis in 9 Large Hospitals in Belgium[NCT04997915] | 1,286 participants (Actual) | Observational | 2020-02-01 | Completed | |||
| Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial[NCT02948998] | Phase 4 | 260 participants (Anticipated) | Interventional | 2018-05-14 | Not yet recruiting | ||
| Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up[NCT02064218] | 0 participants | Observational | 2007-11-30 | Recruiting | |||
| Ending Subclinical Heart Failure Using an Aldosterone and Natriuretic Peptide Targeted Treatment in HIV--The ENCHANTMENT HIV Study[NCT04153136] | Phase 2 | 50 participants (Anticipated) | Interventional | 2020-09-11 | Recruiting | ||
| Mineralocorticoid Receptor Antagonism for Cardiovascular Health in HIV--The MIRACLE HIV Study[NCT02740179] | 40 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV[NCT01407237] | 30 participants (Actual) | Observational | 2012-01-31 | Completed | |||
| Phase 4 Study of Losartan in Hypertensive Men and Women With Obstructive Sleep Apnea Before and After Continuous Positive Airway Pressure (CPAP) Treatment[NCT00701428] | Phase 4 | 90 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation[NCT03206658] | Phase 3 | 90 participants (Anticipated) | Interventional | 2017-08-01 | Not yet recruiting | ||
| Clinical Trial to Reverse Early Arterial Stiffening[NCT00366990] | 349 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA[NCT01681823] | Phase 2 | 60 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects[NCT01977859] | Phase 1 | 4 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects[NCT03234751] | Phase 1 | 6 participants (Actual) | Interventional | 2017-07-13 | Completed | ||
| Cardiometabolic Effects of Eplerenone in HIV Infection[NCT02629094] | Phase 2 | 5 participants (Actual) | Interventional | 2015-12-02 | Terminated | ||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
Percentage change (value at 12 months minus value at baseline) in target to background ratio (a measure of arterial inflammation) of the index vessel measured via positron emission tomography/computed tomography (NCT02740179)
Timeframe: 12 Months
| Intervention | percentage change (Median) |
|---|---|
| Eplerenone | -12.4 |
| Placebo | 5.1 |
Change (value at 12 months minus value at baseline) in left ventricular end diastolic volume on cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months
| Intervention | mL (Mean) |
|---|---|
| Eplerenone | -13 |
| Placebo | 10 |
Change (value at 12 months minus value at baseline) in left ventricular mass on cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months
| Intervention | g (Median) |
|---|---|
| Eplerenone | 1 |
| Placebo | 9 |
Change (value at 12 months minus value at baseline) in global circumferential strain (GCS) on cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months
| Intervention | percentage GCS (Median) |
|---|---|
| Eplerenone | -1.3 |
| Placebo | 2.3 |
Change (value at 12 months minus value at baseline) in coronary plaque measured via coronary computed tomography angiogram assessed by coronary calcium score Scale: minimum 0 to maximum no limit, higher score indicates more plaque (NCT02740179)
Timeframe: 12 Months
| Intervention | score on a scale (Median) |
|---|---|
| Eplerenone | 0 |
| Placebo | 5 |
Change (value at 12 months minus value at baseline) in plasma LpPLA2 (NCT02740179)
Timeframe: 12 Months
| Intervention | ng/mL (Median) |
|---|---|
| Eplerenone | 3.0 |
| Placebo | 2.6 |
Change (value at 12 months minus value at baseline) in myocardial fibrosis measured by T1 (a signal intensity that measures fibrosis) via cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months
| Intervention | ms (Median) |
|---|---|
| Eplerenone | 25 |
| Placebo | 1 |
Change (value at 12 months minus value at baseline) in plasma MCP-1 (NCT02740179)
Timeframe: 12 Months
| Intervention | pg/mL (Median) |
|---|---|
| Eplerenone | 285 |
| Placebo | 292 |
Change (value at 12 months minus value at baseline) in plasma sCD163 (NCT02740179)
Timeframe: 12 Months
| Intervention | ng/mL (Median) |
|---|---|
| Eplerenone | -275 |
| Placebo | -160 |
Change (value at 12 months minus value at baseline) in serum NT-proBNP (NCT02740179)
Timeframe: 12 Months
| Intervention | ng/L (Median) |
|---|---|
| Eplerenone | 19.4 |
| Placebo | 2.8 |
Change (value at 12 months minus value at baseline) in plasma hsCRP (NCT02740179)
Timeframe: 12 Months
| Intervention | ng/mL (Median) |
|---|---|
| Eplerenone | 189 |
| Placebo | 591 |
Change (value at 12 months minus value at baseline) in plasma hsIL-6 (NCT02740179)
Timeframe: 12 Months
| Intervention | pg/mL (Median) |
|---|---|
| Eplerenone | -0.8 |
| Placebo | 0.2 |
Change (value at 12 months minus value at baseline) in serum hs-cTnT (NCT02740179)
Timeframe: 12 Months
| Intervention | ng/L (Median) |
|---|---|
| Eplerenone | 0.00 |
| Placebo | 0.00 |
Change (value at 12 months minus value at baseline) in myocardial inflammation measured by extracellular mass index (a measure of the inflammation within the heart) via cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months
| Intervention | g/m^2 (Median) |
|---|---|
| Eplerenone | 0.9 |
| Placebo | -0.7 |
Change (value at 12 months minus value at baseline) in myocardial perfusion assessed by myocardial blood flow measured via cardiac magnetic resonance imaging (NCT02740179)
Timeframe: 12 Months
| Intervention | mL/min/g (Mean) |
|---|---|
| Eplerenone | 0.09 |
| Placebo | -0.53 |
Change (value at 12 months minus value at baseline) in myocardial perfusion assessed by coronary flow reserve measured via cardiac positron emission tomography. Coronary flow reserve is given by the ratio of blood flow at stress during maximal dilation of the coronary arteries to blood flow at rest. (NCT02740179)
Timeframe: 12 Months
| Intervention | unitless (Mean) |
|---|---|
| Eplerenone | 0.01 |
| Placebo | -0.07 |
Mean change in intraventricular septum percentage of lipid by MR spectroscopy. This was calculated by subtracting the baseline intraventicular septum percentage value of lipid from the week 24 intraventicular septum percentage value of lipid by MR spectroscopy. (NCT02629094)
Timeframe: 24 weeks
| Intervention | percentage of lipid (Mean) |
|---|---|
| Eplerenone | -0.33 |
Mean change in hepatic percentage of lipid by MR spectroscopy. This was calculated by subtracting the baseline hepatic percentage value of lipid from the week 24 hepatic percentage value of lipid by MR spectroscopy. (NCT02629094)
Timeframe: 24 weeks
| Intervention | percentage of lipid (Mean) |
|---|---|
| Eplerenone | 13 |
45 reviews available for aldosterone and Inflammation
| Article | Year |
|---|---|
Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies.
Topics: Acute Kidney Injury; Aldosterone; Angiotensins; Antibodies, Monoclonal, Humanized; Autopsy; Biopsy; | 2022 |
Mosaic theory revised: inflammation and salt play central roles in arterial hypertension.
Topics: Aldosterone; Humans; Hypertension; Inflammation; Sodium Chloride, Dietary | 2022 |
Secondary diabetes mellitus due to primary aldosteronism.
Topics: Aldosterone; Diabetes Mellitus; Glucocorticoids; Glucose; Humans; Hyperaldosteronism; Hypokalemia; I | 2023 |
Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
Topics: Aldosterone; Diabetes Mellitus, Type 2; Fibrosis; Humans; Hyperkalemia; Inflammation; Mineralocortic | 2022 |
Vascular and inflammatory mineralocorticoid receptors in kidney disease.
Topics: Aldosterone; Animals; Endothelium, Vascular; Humans; Inflammation; Kidney Diseases; Muscle, Smooth, | 2020 |
Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis.
Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Immunity, Innate; Inflammati | 2020 |
Oxidative Stress: A Unifying Paradigm in Hypertension.
Topics: Aldosterone; Angiotensin II; Endothelin-1; Endothelium, Vascular; Humans; Hypertension; Inflammation | 2020 |
What every Intensivist should know about COVID-19 associated acute kidney injury.
Topics: Acute Kidney Injury; Aldosterone; Anticoagulants; COVID-19; Critical Care; Critical Illness; Humans; | 2020 |
Pathophysiology of Hypertension: The Mosaic Theory and Beyond.
Topics: Aldosterone; Angiotensin II; Blood Pressure; Blood Vessels; Body Fluids; Central Nervous System; Hum | 2021 |
Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2013 |
Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.
Topics: Aldosterone; Animals; Aromatase Inhibitors; Cardiovascular System; Cytochrome P-450 CYP11B2; Endothe | 2013 |
[Renin-aldosterone and bone metabolism].
Topics: Acute Kidney Injury; Aldosterone; Angiotensin II; Animals; Bone and Bones; Calcium; Cardiovascular D | 2014 |
[Organ damage and cardiorenal syndrome in acute heart failure].
Topics: Aldosterone; Cardiac Output; Cardio-Renal Syndrome; Comorbidity; Endothelium, Vascular; Heart Failur | 2014 |
Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Aldosterone; Animals; Blood Pressure; Clinical Trials as Topi | 2015 |
Relevance of SGK1 in structural, functional and molecular alterations produced by aldosterone in heart.
Topics: Aldosterone; Animals; Cardiomegaly; Connective Tissue Growth Factor; Endothelium, Vascular; Fibrosis | 2014 |
Aldosterone blockade in CKD: emphasis on pharmacology.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biological | 2015 |
Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone.
Topics: Adrenal Cortex; Aldosterone; Animals; Humans; Immunologic Factors; Immunomodulation; Inflammation; M | 2015 |
Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology.
Topics: Aging; Aldosterone; Cardiovascular Diseases; Eye Diseases; Fibrosis; Humans; Inflammation; Ion Chann | 2016 |
Extracellular volume and aldosterone interaction in chronic kidney disease.
Topics: Aldosterone; Cardiovascular Diseases; Chronic Disease; Extracellular Fluid; Fibrosis; Humans; Inflam | 2009 |
Pharmacological treatment for heart failure: a view from the brain.
Topics: Aldosterone; Angiotensins; Animals; Blood-Brain Barrier; Brain; Cardiovascular Agents; Cell Communic | 2009 |
[The renin-angiotensin system].
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2009 |
Aldosterone: effects on the kidney and cardiovascular system.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2010 |
Aldosterone and inflammation.
Topics: Aldosterone; Animals; Cytochrome P-450 CYP11B2; Disease Models, Animal; Humans; Inflammation; Minera | 2010 |
Midkine regulation of the renin-angiotensin system.
Topics: Acetylcholinesterase; Acute Kidney Injury; Aldosterone; Angiotensin II; Animals; Central Nervous Sys | 2010 |
Mineralocorticoid receptor antagonists and the metabolic syndrome.
Topics: Aldosterone; Antihypertensive Agents; Eplerenone; Humans; Hypertension; Inflammation; Insulin Resist | 2010 |
The role of aldosterone in the metabolic syndrome.
Topics: Aldosterone; Cardiovascular System; Humans; Inflammation; Insulin Resistance; Lipids; Metabolic Synd | 2011 |
Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule?
Topics: Aldosterone; Animals; Blood Pressure; Brain; Cardiovascular Diseases; Cardiovascular Physiological P | 2011 |
Mineralocorticoid receptor blockade in chronic kidney disease.
Topics: Aldosterone; Diabetes Mellitus; Humans; Hypertension; Inflammation; Kidney Failure, Chronic; Mineral | 2011 |
Aldosterone, mineralocorticoid receptor and the metabolic syndrome: role of the mineralocorticoid receptor antagonists.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Disease Progression; Endothelium, Vascular; Humans; I | 2012 |
Inflammation in hypertension: current therapeutic approaches.
Topics: Adipose Tissue; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Biomarkers; Cell Adhe | 2011 |
Extrarenal effects of aldosterone.
Topics: Aldosterone; Endothelium, Vascular; Heart; Humans; Hypertension; Inflammation; Metabolic Syndrome; M | 2012 |
Aldosterone resurgens--letter from EPHESUS.
Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiovascular Diseases; Eplerenone; Humans; Inflammation | 2003 |
Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets.
Topics: Aldosterone; Animals; Biomarkers; Coronary Circulation; Fibrosis; Heart Failure; Humans; Hyperaldost | 2003 |
Obesity and hypertension.
Topics: Adipose Tissue; Aldosterone; Body Mass Index; Cardiovascular System; Genetic Predisposition to Disea | 2003 |
Hypertension and obesity.
Topics: Adipose Tissue; Aldosterone; Animals; Body Mass Index; Humans; Hypertension; Inflammation; Insulin R | 2004 |
Hypertension and obesity.
Topics: Adipose Tissue; Aldosterone; Animals; Body Mass Index; Humans; Hypertension; Inflammation; Insulin R | 2004 |
Hypertension and obesity.
Topics: Adipose Tissue; Aldosterone; Animals; Body Mass Index; Humans; Hypertension; Inflammation; Insulin R | 2004 |
Hypertension and obesity.
Topics: Adipose Tissue; Aldosterone; Animals; Body Mass Index; Humans; Hypertension; Inflammation; Insulin R | 2004 |
[PPARs and fibrosis].
Topics: Adipocytes; Aldosterone; Animals; Connective Tissue Growth Factor; Fibrosis; Immediate-Early Protein | 2005 |
[Aldosterone blockade in essential hypertension].
Topics: Aldosterone; Fibrosis; Humans; Hypertension; Inflammation; Mineralocorticoid Receptor Antagonists | 2005 |
Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation.
Topics: Aldosterone; Animals; Cardiovascular Diseases; Cardiovascular System; Endothelium, Vascular; Humans; | 2005 |
Renin-angiotensin system block and atrial fibrillation.
Topics: Aldosterone; Animals; Atrial Fibrillation; Electric Countershock; Humans; Inflammation; Renin-Angiot | 2005 |
Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Regulation of NaCl transport in the renal collecting duct: lessons from cultured cells.
Topics: Aldosterone; Animals; Cells, Cultured; Gonadal Steroid Hormones; Humans; Inflammation; Ion Transport | 2006 |
Aldosterone, mineralocorticoid receptors, and vascular inflammation.
Topics: Aldosterone; Animals; Blood Vessels; Humans; Inflammation; Reactive Oxygen Species; Receptors, Miner | 2007 |
Aldosterone and vascular inflammation.
Topics: Aldosterone; Animals; Atherosclerosis; Blood Vessels; Cardiovascular Diseases; Humans; Inflammation; | 2008 |
Translating molecular discoveries into new therapies for atherosclerosis.
Topics: Aldosterone; Animals; Atherosclerosis; Humans; Inflammation; Lipoproteins; Renin-Angiotensin System; | 2008 |
Aldosterone and the vascular system.
Topics: Aldosterone; Animals; Endothelium; Humans; Inflammation; Vasodilation | 2008 |
7 trials available for aldosterone and Inflammation
| Article | Year |
|---|---|
Blockade of the mineralocorticoid receptor improves markers of human endothelial cell dysfunction and hematological indices in a mouse model of sickle cell disease.
Topics: Aldosterone; Anemia, Sickle Cell; Animals; Disease Models, Animal; Endothelial Cells; Endothelin-1; | 2023 |
Procalcitonin and the inflammatory response to salt in essential hypertension: a randomized cross-over clinical trial.
Topics: Aldosterone; Biomarkers; Calcitonin; Calcitonin Gene-Related Peptide; Cross-Over Studies; Humans; Hy | 2013 |
The effects of canrenone on inflammatory markers in patients with metabolic syndrome.
Topics: Aged; Aldosterone; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Canrenon | 2015 |
RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients.
Topics: Adiposity; Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Female; HI | 2015 |
RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients.
Topics: Adiposity; Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Female; HI | 2015 |
RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients.
Topics: Adiposity; Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Female; HI | 2015 |
RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients.
Topics: Adiposity; Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Female; HI | 2015 |
RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients.
Topics: Adiposity; Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Female; HI | 2015 |
RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients.
Topics: Adiposity; Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Female; HI | 2015 |
RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients.
Topics: Adiposity; Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Female; HI | 2015 |
RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients.
Topics: Adiposity; Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Female; HI | 2015 |
RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients.
Topics: Adiposity; Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Female; HI | 2015 |
Neuroendocrine and Inflammatory Responses to Losartan and Continuous Positive Airway Pressure in Patients with Hypertension and Obstructive Sleep Apnea. A Randomized Controlled Trial.
Topics: Aldosterone; Antihypertensive Agents; Blood Pressure; Case-Control Studies; Continuous Positive Airw | 2016 |
Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults.
Topics: Adult; Aldosterone; Ankle Brachial Index; Biomarkers; Blood Pressure; Cross-Sectional Studies; Exerc | 2012 |
RALES, EPHESUS and redox.
Topics: Aldosterone; Animals; Heart Failure; Humans; Inflammation; Mineralocorticoid Receptor Antagonists; M | 2005 |
91 other studies available for aldosterone and Inflammation
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Renal artery occlusive disease, renin-angiotensin-aldosterone, inflammation, and refractory arterial hypertension, a half-century's perspective.
Topics: Aldosterone; Angiotensin II; Angiotensins; Blood Pressure; Humans; Hypertension; Inflammation; Renal | 2022 |
Serum levels of autoantibodies against the angiotensin II type I receptor are not associated with serum dicarbonyl or AGE levels in patients with an aldosterone-producing adenoma.
Topics: Adenoma; Aldosterone; Angiotensin II; Autoantibodies; Chromatography, Liquid; Glycation End Products | 2023 |
Serum levels of autoantibodies against the angiotensin II type I receptor are not associated with serum dicarbonyl or AGE levels in patients with an aldosterone-producing adenoma.
Topics: Adenoma; Aldosterone; Angiotensin II; Autoantibodies; Chromatography, Liquid; Glycation End Products | 2023 |
Serum levels of autoantibodies against the angiotensin II type I receptor are not associated with serum dicarbonyl or AGE levels in patients with an aldosterone-producing adenoma.
Topics: Adenoma; Aldosterone; Angiotensin II; Autoantibodies; Chromatography, Liquid; Glycation End Products | 2023 |
Serum levels of autoantibodies against the angiotensin II type I receptor are not associated with serum dicarbonyl or AGE levels in patients with an aldosterone-producing adenoma.
Topics: Adenoma; Aldosterone; Angiotensin II; Autoantibodies; Chromatography, Liquid; Glycation End Products | 2023 |
Serum levels of autoantibodies against the angiotensin II type I receptor are not associated with serum dicarbonyl or AGE levels in patients with an aldosterone-producing adenoma.
Topics: Adenoma; Aldosterone; Angiotensin II; Autoantibodies; Chromatography, Liquid; Glycation End Products | 2023 |
Serum levels of autoantibodies against the angiotensin II type I receptor are not associated with serum dicarbonyl or AGE levels in patients with an aldosterone-producing adenoma.
Topics: Adenoma; Aldosterone; Angiotensin II; Autoantibodies; Chromatography, Liquid; Glycation End Products | 2023 |
Serum levels of autoantibodies against the angiotensin II type I receptor are not associated with serum dicarbonyl or AGE levels in patients with an aldosterone-producing adenoma.
Topics: Adenoma; Aldosterone; Angiotensin II; Autoantibodies; Chromatography, Liquid; Glycation End Products | 2023 |
Serum levels of autoantibodies against the angiotensin II type I receptor are not associated with serum dicarbonyl or AGE levels in patients with an aldosterone-producing adenoma.
Topics: Adenoma; Aldosterone; Angiotensin II; Autoantibodies; Chromatography, Liquid; Glycation End Products | 2023 |
Serum levels of autoantibodies against the angiotensin II type I receptor are not associated with serum dicarbonyl or AGE levels in patients with an aldosterone-producing adenoma.
Topics: Adenoma; Aldosterone; Angiotensin II; Autoantibodies; Chromatography, Liquid; Glycation End Products | 2023 |
Association of Aldosterone with Mortality in the General Population.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Humans; Hypertension; Inflammatio | 2023 |
Adverse effects of an aldosterone synthase (CYP11B2) inhibitor, fadrozole (FAD286), on inflamed rat colon.
Topics: Aldosterone; Animals; Colon; Cytochrome P-450 CYP11B2; Fadrozole; Iatrogenic Disease; Inflammation; | 2023 |
Esaxerenone Inhibits Renal Angiogenesis and Endothelial-Mesenchymal Transition via the VEGFA and TGF-β1 Pathways in Aldosterone-Infused Mice.
Topics: Aldosterone; Animals; Endothelial Cells; Epithelial-Mesenchymal Transition; Fibrosis; Inflammation; | 2023 |
Aldosterone Synthase in Peripheral Sensory Neurons Contributes to Mechanical Hypersensitivity during Local Inflammation in Rats.
Topics: Adjuvants, Immunologic; Aldosterone; Animals; Cytochrome P-450 CYP11B2; Freund's Adjuvant; Ganglia, | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Endocrine and metabolic link to coronavirus infection.
Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type | 2020 |
Relation of Plasma Renin Activity to Subclinical Peripheral and Coronary Artery Disease (from the Multiethnic Study of Atherosclerosis).
Topics: Aldosterone; Ankle Brachial Index; Atherosclerosis; Biomarkers; Coronary Artery Disease; Female; Hum | 2020 |
Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity.
Topics: Aged; Aged, 80 and over; Aldosterone; Atherosclerosis; Biomarkers; Carotid Arteries; Cross-Sectional | 2020 |
Neuronal aldosterone elicits a distinct genomic response in pain signaling molecules contributing to inflammatory pain.
Topics: Aldosterone; Animals; Cytochrome P-450 CYP11B2; Hyperalgesia; Inflammation; Male; Mineralocorticoid | 2020 |
TRIF/miR-34a mediates aldosterone-induced cardiac inflammation and remodeling.
Topics: Adaptor Proteins, Vesicular Transport; Aldosterone; Animals; Animals, Newborn; Cardiomegaly; Fibrosi | 2020 |
Fabry disease patients have an increased risk of stroke in the COVID-19 ERA. A hypothesis.
Topics: Aldosterone; Angiotensin-Converting Enzyme 2; COVID-19; Endothelium, Vascular; Fabry Disease; Female | 2020 |
Angiotensin aldosterone inhibitors improve survival and ameliorate kidney injury induced by sepsis through suppression of inflammation and apoptosis.
Topics: Aldosterone; Angiotensins; Animals; Apoptosis; Disease Models, Animal; Humans; Inflammation; Kidney; | 2022 |
Associations of aldosterone and renin concentrations with inflammation-the Study of Health in Pomerania and the German Conn's Registry.
Topics: Adult; Aldosterone; Biomarkers; C-Reactive Protein; Cohort Studies; Female; Fibrinogen; Germany; Hum | 2017 |
Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Biomarkers; Blood Pressure; Cardiovascular Diseases; Ch | 2017 |
Primary aldosteronism patients show skin alterations and abnormal activation of glucocorticoid receptor in keratinocytes.
Topics: Aged; Aged, 80 and over; Aldosterone; Animals; Cells, Cultured; Cytokines; Female; Humans; Hyperaldo | 2017 |
Neutrophil Gelatinase-Associated Lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation.
Topics: Aldosterone; Animals; Atrial Remodeling; Cell Proliferation; Cells, Cultured; Fibroblasts; Fibrosis; | 2018 |
Uterine fibroids and risk of hypertension: Implication of inflammation and a possible role of the renin-angiotensin-aldosterone system.
Topics: Aldosterone; Cardiovascular Diseases; Female; Humans; Hypertension; Inflammation; Leiomyoma; Renin; | 2018 |
SB-216763, a GSK-3β inhibitor, protects against aldosterone-induced cardiac, and renal injury by activating autophagy.
Topics: Aldosterone; Animals; Autophagy; Cytokines; Fibrosis; Glycogen Synthase Kinase 3 beta; Heart Disease | 2018 |
Relationship between sodium, pentraxin-3 and aldosterone in inflammation and cardiovascular risk.
Topics: Aldosterone; C-Reactive Protein; Cardiovascular Diseases; Humans; Hypertension; Inflammation; Potass | 2018 |
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice.
Topics: Aldosterone; Animals; Aorta; Apolipoproteins E; Endothelium, Vascular; Inflammation; Lipid Metabolis | 2018 |
Aldosterone induced up-expression of ICAM-1 and ET-1 in pancreatic islet endothelium may associate with progression of T2D.
Topics: Aldosterone; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Progressio | 2019 |
Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation.
Topics: Aldosterone; Animals; Cardiomegaly; Cardiovascular System; CD11 Antigens; Coculture Techniques; Dend | 2019 |
Aldosterone levels and inflammatory stimulation in essential hypertensive patients.
Topics: Adult; Aged; Aldosterone; Biomarkers; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; C | 2013 |
Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism.
Topics: Aldosterone; Animals; Aorta, Abdominal; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Chemoki | 2013 |
Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity.
Topics: Adipose Tissue; Aldosterone; Animals; Antioxidants; Aorta; Cyclooxygenase 1; Cyclooxygenase Inhibito | 2013 |
Effect of renal sympathetic denervation on atrial substrate remodeling in ambulatory canines with prolonged atrial pacing.
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Atrial Fibrillation; Atrial Natriuretic Factor; Atr | 2013 |
Marine natural product des-O-methyllasiodiplodin effectively lowers the blood glucose level in db/db mice via ameliorating inflammation.
Topics: 3T3-L1 Cells; Aldosterone; Animals; Apocynaceae; Blood Glucose; Cytokines; Diabetes Mellitus, Type 2 | 2013 |
Aldosterone-induced inflammatory response of mesangial cells via angiotension II receptors.
Topics: Aldosterone; Animals; Chemokine CCL2; Dexamethasone; Diabetes Mellitus, Experimental; Gene Knockdown | 2015 |
Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs.
Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Canrenone; Humans; Hypertension; | 2014 |
Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in aldosterone-salt-treated rats.
Topics: Aldosterone; Animals; Blood Pressure; Caspase 1; DNA Nucleotidylexotransferase; Epithelial Sodium Ch | 2014 |
4-Hydroxychalcone attenuates hyperaldosteronism, inflammation, and renal injury in cryptochrome-null mice.
Topics: Aldosterone; Animals; Blood Pressure; Chalcones; Cryptochromes; Hyperaldosteronism; Inflammation; In | 2014 |
Interleukin-33/ST2 system attenuates aldosterone-induced adipogenesis and inflammation.
Topics: 3T3-L1 Cells; Adipogenesis; Adipose Tissue; Aldosterone; Animals; Diet, High-Fat; Inflammation; Inte | 2015 |
Paricalcitol Inhibits Aldosterone-Induced Proinflammatory Factors by Modulating Epidermal Growth Factor Receptor Pathway in Cultured Tubular Epithelial Cells.
Topics: ADAM Proteins; ADAM17 Protein; Aldosterone; Cell Line; Cell Proliferation; Epithelial Cells; ErbB Re | 2015 |
Rotenone Attenuates Renal Injury in Aldosterone-Infused Rats by Inhibiting Oxidative Stress, Mitochondrial Dysfunction, and Inflammasome Activation.
Topics: Adenosine Triphosphate; Aldosterone; Animals; Carrier Proteins; DNA, Mitochondrial; Glomeruloscleros | 2015 |
TAK-242, a Toll-Like Receptor 4 Antagonist, Protects against Aldosterone-Induced Cardiac and Renal Injury.
Topics: Acute Kidney Injury; Aldosterone; Animals; Cytokines; Heart Diseases; Hemodynamics; Inflammation; Ma | 2015 |
Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats.
Topics: Aldosterone; Animals; Fibrosis; Inflammation; Kidney; Kidney Diseases; Macrophages; Male; Mineraloco | 2016 |
Analysis of Ionomic Profiles of Canine Hairs Exposed to Lipopolysaccharide (LPS)-Induced Stress.
Topics: Aldosterone; Animals; Cytokines; Dogs; Hair; Hydrocortisone; Inflammation; Lipopolysaccharides; Prin | 2016 |
The story of spironolactones from 1957 to now: from sodium balance to inflammation.
Topics: Aldosterone; History, 20th Century; History, 21st Century; Hypertension; Inflammation; Mineralocorti | 2016 |
Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor.
Topics: Aldosterone; Animals; Blood Pressure; Brain; Cerebrovascular Circulation; Cytokines; Endothelial Cel | 2016 |
Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II Type 1 Receptor Blockers; A | 2008 |
Relations of biomarkers representing distinct biological pathways to left ventricular geometry.
Topics: Aldosterone; Biomarkers; C-Reactive Protein; Cardiomegaly; Electrocardiography; Female; Fibrin; Hear | 2008 |
Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?
Topics: Aldosterone; Angiotensin II; Blood Pressure; Cardiovascular System; ErbB Receptors; Homeostasis; Hyp | 2009 |
Absence of circulating aldosterone attenuates foreign body reaction around surgical sutures.
Topics: Adrenalectomy; Aldosterone; Animals; Disease Models, Animal; Granuloma, Foreign-Body; Inflammation; | 2010 |
Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community.
Topics: Aged; Aldosterone; Atrial Natriuretic Factor; Biomarkers; C-Reactive Protein; Cardiovascular Disease | 2009 |
Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis.
Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Chemokine CCL2; Female; Fibrosis; Gene Expression | 2009 |
Central mineralocorticoid receptors and cardiovascular disease.
Topics: Aldosterone; Animals; Blood Vessels; Brain; Cardiovascular Diseases; Hemodynamics; Humans; Inflammat | 2009 |
The balance between gluco- and mineralo-corticoid action critically determines inflammatory adipocyte responses.
Topics: Adipocytes; Adipokines; Aldosterone; Animals; Anti-Inflammatory Agents; Cell Differentiation; Cell L | 2010 |
Increased plasma levels of osteopontin are associated with activation of the renin-aldosterone system and with myocardial and coronary microvascular damage in dilated cardiomyopathy.
Topics: Aldosterone; Biomarkers; Cardiomyopathy, Dilated; Coronary Circulation; Female; Humans; Inflammation | 2010 |
Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity.
Topics: Aldosterone; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Cell Line; Fibroblas | 2010 |
Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects".
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Capillaries; Collagen; Cytochrome b Group; Desoxyco | 2010 |
Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients.
Topics: Adult; Aldosterone; Biomarkers; Blood Pressure; C-Reactive Protein; Cardiomyopathies; Case-Control S | 2010 |
FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice.
Topics: Aldosterone; Animals; Apolipoproteins E; Atherosclerosis; Cell Line; Cytochrome P-450 CYP11B2; Diet, | 2010 |
HO-1 attenuates hypertension-induced inflammation/oxidative stress: support from Bartter's/Gitelman's patients.
Topics: Aldosterone; Angiotensin II; Bartter Syndrome; Blood Pressure; Heme Oxygenase-1; Humans; Hypertensio | 2010 |
Macrophage activation is responsible for loss of anticontractile function in inflamed perivascular fat.
Topics: Adipose Tissue; Aldosterone; Animals; CD11b Antigen; Cell Hypoxia; Dose-Response Relationship, Drug; | 2011 |
New take on the role of angiotensin II in cardiac hypertrophy and fibrosis.
Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Fibrosis; Humans; Hypertension; Inflammation; Mi | 2011 |
Vascular proinflammatory responses by aldosterone are mediated via c-Src trafficking to cholesterol-rich microdomains: role of PDGFR.
Topics: Aldosterone; Animals; Caveolae; Cholesterol; CSK Tyrosine-Protein Kinase; Inflammation; Membrane Mic | 2011 |
Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney.
Topics: Albuminuria; Aldosterone; Animals; Blood Pressure; Eplerenone; Fibrosis; Inflammation; Kidney; Male; | 2011 |
A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone.
Topics: Aldosterone; Animals; Blood Pressure; Blotting, Western; Collagen; Cytokines; Disease Models, Animal | 2011 |
Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Fibrosis; Heart; Immediate-Early Proteins; Infla | 2012 |
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Biomarkers; Blood Pressure; Cytochrome P-450 CYP11B2; D | 2012 |
[The role of aldosterone and IL-6 in the pathogenesis of inflammation in familial Mediterranean fever].
Topics: Adult; Aldosterone; Amyloidosis; Colchicine; Familial Mediterranean Fever; Genotype; Humans; Inflamm | 2012 |
Aldosterone synergizes with peripheral inflammation to induce brain IL-1β expression and depressive-like effects.
Topics: Aldosterone; Animals; Behavior, Animal; Cytokines; Depression; Depressive Disorder; Inflammation; In | 2012 |
Galectin-3 mediates aldosterone-induced vascular fibrosis.
Topics: Aldosterone; Animals; Blood Pressure; Cells, Cultured; Collagen Type I; Disease Models, Animal; Fibr | 2013 |
Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice.
Topics: Aldosterone; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Biomarkers; Diet, Sodium-Restricted | 2014 |
Aldosterone-induced inflammation in the rat heart : role of oxidative stress.
Topics: Aldosterone; Animals; Antioxidants; Cardiomyopathies; Cell Division; Cell Movement; Fibrosis; Heart; | 2002 |
PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Blood Pressure; Body Weight; Cell Adhesion Molecules; C | 2002 |
Anticortisol action of aldosterone.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Aldosterone; Inflammation | 1955 |
Effect of aldactone, an antiminera-locorticoid steroid spironolactone, on inflammation.
Topics: Aldosterone; Diuretics; Hydrocortisone; Inflammation; Mineralocorticoid Receptor Antagonists; Spiron | 1961 |
[The antiphlogistic effect and mechanism of action of spironolactone].
Topics: Aldosterone; Diuretics; Inflammation; Mineralocorticoid Receptor Antagonists; Spironolactone | 1962 |
The use of anti-inflammatory steroids in the rheumatic and collagen diseases.
Topics: Aldosterone; Collagen Diseases; Cortisone; Desoxycorticosterone; Hydrocortisone; Inflammation; Predn | 1963 |
[GLOMERULOTROPHIN AND EXPERIMENTAL INFLAMMATION].
Topics: Abscess; Aldosterone; Capillary Permeability; Edema; Granuloma; Heterocyclic Compounds; Inflammation | 1964 |
From inflammation to fibrosis: a stiff stretch of highway.
Topics: Aldosterone; Angiotensin II; Animals; Aorta, Abdominal; Apoptosis; Cell Adhesion Molecules; Collagen | 2004 |
Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells.
Topics: Aldosterone; Canrenoic Acid; Cells, Cultured; Cyproterone Acetate; Cytokines; Enzyme-Linked Immunoso | 2004 |
Inhibition of Na+-H+ exchange by cariporide reduces inflammation and heart failure in rabbits with myocardial infarction.
Topics: Aldosterone; Animals; C-Reactive Protein; Electrocardiography; Guanidines; Heart Failure; Inflammati | 2004 |
Aldosterone, inflammation, and preeclampsia.
Topics: Aldosterone; Female; Humans; Inflammation; Pre-Eclampsia; Pregnancy | 2005 |
Hyperparathyroidism and the calcium paradox of aldosteronism.
Topics: Aldosterone; Animals; Bone Density; Bone Resorption; Calcium; Hyperaldosteronism; Hyperparathyroidis | 2005 |
Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage.
Topics: Adrenal Glands; Adrenalectomy; Aldosterone; Angiotensin II; Angiotensinogen; Animals; Animals, Genet | 2005 |
Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes.
Topics: Adipocytes; Adipose Tissue, Brown; Aldosterone; Animals; Blotting, Western; Carrier Proteins; Chemok | 2005 |
The proinflammatory heart failure phenotype: a case of integrative physiology.
Topics: Aldosterone; Animals; Calcium; Coronary Circulation; Cytokines; Disease Models, Animal; Heart Failur | 2005 |
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cells, Cultured; Chemokine CCL2; Chole | 2006 |
Chronic fatigue syndrome and high allostatic load.
Topics: Adult; Age Factors; Aldosterone; Algorithms; Body Mass Index; Case-Control Studies; Data Interpretat | 2006 |
Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats.
Topics: Adrenalectomy; Albuminuria; Aldosterone; Animals; Blood Glucose; Collagen Type IV; Cytochrome P-450 | 2008 |
Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines.
Topics: 3T3-L1 Cells; Adipokines; Adiponectin; Adipose Tissue; Aldosterone; Animals; Biomarkers; Body Weight | 2008 |
Crosstalk between the heme oxygenase system, aldosterone, and phospholipase C in hypertension.
Topics: Aldosterone; Animals; Aorta; Blood Pressure; Calcium; Cyclic GMP; Cyclic GMP-Dependent Protein Kinas | 2008 |
Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Blood Vessels; Body Weight; Cell Cycle Protein | 2002 |
Increased progesterone receptor concentrations in bladder lesions of estrogen-treated Syrian hamsters.
Topics: Aldosterone; Animals; Binding, Competitive; Cricetinae; Cytosol; Dihydrotestosterone; Estradiol; Est | 1979 |
Isolated aldosterone deficiency in a patient with autoimmune adrenalitis.
Topics: Adrenal Gland Diseases; Adult; Aldosterone; Autoimmune Diseases; Female; Humans; Inflammation | 1991 |
Acute phase responses of plasma angiotensinogen and T-kininogen in rats.
Topics: Acute-Phase Reaction; Adrenalectomy; Aldosterone; Angiotensinogen; Animals; Dexamethasone; Inflammat | 1987 |
Adrenal corticosteroids--physiological considerations.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Aldosterone; Androgens; Angiotensin II; Blood | 1972 |